Invesco Biotechnology & Genome ETF (NYSEARCA:PBE – Get Free Report) was the target of a significant increase in short interest in August. As of August 14th, there was short interest totaling 17,905 shares, an increase of 102.8% from the July 30th total of 8,827 shares. Approximately 0.6% of the company’s stock are sold short. Based on an average daily volume of 102,216 shares, the days-to-cover ratio is currently 0.2 days.
Invesco Biotechnology & Genome ETF Trading Down 2.3%
Shares of PBE opened at $96.32 on Friday. Invesco Biotechnology & Genome ETF has a 12 month low of $67.69 and a 12 month high of $98.82. The firm has a fifty day simple moving average of $92.06 and a 200 day simple moving average of $84.77. The stock has a market capitalization of $303.41 million, a price-to-earnings ratio of 20.44 and a beta of 0.70.
Hedge Funds Weigh In On Invesco Biotechnology & Genome ETF
A number of large investors have recently modified their holdings of the business. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Invesco Biotechnology & Genome ETF by 9,169.5% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 342,971 shares of the company’s stock valued at $28,175,000 after acquiring an additional 339,271 shares in the last quarter. United Capital Financial Advisors LLC bought a new stake in Invesco Biotechnology & Genome ETF during the third quarter worth about $5,946,000. Royal Bank of Canada raised its holdings in Invesco Biotechnology & Genome ETF by 22.3% during the first quarter. Royal Bank of Canada now owns 75,402 shares of the company’s stock worth $4,783,000 after acquiring an additional 13,767 shares in the last quarter. Dynamic Advisor Solutions LLC acquired a new position in Invesco Biotechnology & Genome ETF during the second quarter valued at approximately $484,000. Finally, LPL Financial LLC boosted its position in Invesco Biotechnology & Genome ETF by 5.0% during the fourth quarter. LPL Financial LLC now owns 97,304 shares of the company’s stock valued at $7,994,000 after purchasing an additional 4,617 shares during the last quarter.
Invesco Biotechnology & Genome ETF Company Profile
PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.
Further Reading
- Five stocks we like better than Invesco Biotechnology & Genome ETF
- Venture Into High-Volatility Corners of the Market With These 3 ETFs
- 3 Retail Stocks to Watch After a Big Consumer Earnings Week
- Amazon’s Zoox Push Tests Tesla’s Robotaxi Premium as Waymo Widens Its Lead
- MarketBeat Week in Review – 08/24 – 08/28
Receive News & Ratings for Invesco Biotechnology & Genome ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invesco Biotechnology & Genome ETF and related companies with MarketBeat.com's FREE daily email newsletter.
